Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 2/8/2020
SIETES contiene 93072 citas

 
 
 1 a 20 de 108 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Dawson R, Diacon AH, Everitt D, van Niekerk C, Ronald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp LI, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 2015;385:1738-47. [Ref.ID 99082]
2. Cita con resumen
Pietersen E, Ignatius E, Streicher EM, Mastrapa B, Padanilam X, Pooran A, Badri M, Lesosky M, van Helden P, Sirgel FA, Warren R, Dheda K. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet 2014;383:1230-9. [Ref.ID 97376]
3. Cita con resumen
Díaz Cuevas Z, Rodríquez Lozano B, Campos Gutierrez S, Lecuona Fernández M. Lesiones cutáneas nodulares en paciente con artritis reumatoide en tratamiento con anti-factor de necrosis tumoral-alfa.. Med Clin (Barc) 2014;142:183-4. [Ref.ID 97319]
4.Tiene citas relacionadas Cita con resumen
Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, McShane H, the MVA85A Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013;381:1021-8. [Ref.ID 95119]
5.Tiene citas relacionadas Cita con resumen
Dye C, Fine PE. A major event for new tuberculosis vaccines. Lancet 2013;381:972-4. [Ref.ID 95117]
6.
Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon H-S, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee J-K, Lee D, Kim CT, Dartois V, Park SK, Cho S-N, Barry III CE. Linezolid for treament of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367:1508-18. [Ref.ID 93890]
7. Cita con resumen
Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bilven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh Jr CR, Chaisson RE, for the TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155-66. [Ref.ID 91928]
8. Cita con resumen
Woodcock J, Griffin JP, Behman RE. Development of novel combination therapies. N Engl J Med 2011;364:985-7. [Ref.ID 90493]
9.Tiene citas relacionadas
Tageja N, Sharma V. Multidrug-resistant tuberculosis in India. Lancet 2010;376:682-3. [Ref.ID 89249]
10.Tiene citas relacionadas
Dheda K, Badri M, Zumla A, on behalf of all other authors. Extensively drug-resistant tuberculosis in South Africa. Authors' reply. Lancet 2010;376:681-2. [Ref.ID 89248]
11.Tiene citas relacionadas
Bhuniya S. Extensively drug-resistant tuberculosis in South Africa. Lancet 2010;376:681. [Ref.ID 89247]
12.Tiene citas relacionadas
Cox H, Ford N, McDermid C, Van Cutsem G, Goemaere E. Extensively drug-resistant tuberculosis in South Africa. Lancet 2010;376:681. [Ref.ID 89246]
13.Tiene citas relacionadas
Kaufmann SHE, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet 2010;375:2100-19. [Ref.ID 88671]
14.Tiene citas relacionadas
Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010;375:2100-9. [Ref.ID 88670]
15. Cita con resumen
Anónimo. Acupuncture transmitted infections. BMJ 2010;340:1151-2. [Ref.ID 88622]
16.Tiene citas relacionadas
Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, Perkins MD, Zumla A. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010;375:1920-37. [Ref.ID 88609]
17.Tiene citas relacionadas
Harries AD, Zachariah R, Corbett EL, Lawn SD, Santos-Filho ET, Chimzizi R, Harrington M, Maher D, Williams BG, De Cock KM. The HIV-associated tuberculosis epidemic - when will we act?. Lancet 2010;375:1906-19. [Ref.ID 88608]
18.Tiene citas relacionadas
Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, Jensen P, Bayona J. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010;375:1830-43. [Ref.ID 88539]
19.Tiene citas relacionadas
Lönnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, Raviglione MC. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 2010;375:1814-29. [Ref.ID 88538]
20.Tiene citas relacionadas
Ghebreyesus TA, Kazatchkine M, Sidibé M, Nakatani H. Tuberculosis and HIV: time for an intensified response. Lancet 2010;375:1757-8. [Ref.ID 88537]
Seleccionar todas
 
 1 a 20 de 108 siguiente >>